Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 13/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468560 | 0.79 | PLK1 (0.45) | PLK1 | |
| SCHEMBL31668867 | 0.75 | CYP1A2 (0.43) | GAACYP2C9 | |
| SCHEMBL3039694 | 0.74 | FYN (0.65) | — | |
| SCHEMBL3040935 | 0.74 | FYN (0.65) | — | |
| SCHEMBL3037462 | 0.74 | PLK1 (0.43) | PLK1POLB | |
| SCHEMBL15022761 | 0.73 | ALDH1A1 (0.74) | ALDH1A1GAAHTTHPGDCRHBP | |
| SCHEMBL31629180 | 0.73 | ALDH1A1 (0.74) | ALDH1A1GAAHTTHPGDCRHBP | |
| SCHEMBL2733724 | 0.73 | ALDH1A1 (0.74) | ALDH1A1GAAHTTHPGDCRHBP | |
| SCHEMBL2792928 | 0.73 | ALDH1A1 (0.74) | ALDH1A1GAAHTTHPGDCRHBP | |
| SCHEMBL3041409 | 0.73 | HSD17B10 (0.46) | HTTPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | ALDH1A1 4048/4885GAA 3748/4885HTT 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.